Roboz, Gail J

Publications

Sort by

Co-Author Network

Selected publications

A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML). Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 In Process GET IT
Are we ready for precision medicine in acute myeloid leukemia?. Clinical advances in hematology & oncology : H&O. 2016 In Process GET IT
Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. Nature medicine. 2016 In Process GET IT
Times cited: 2
The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure. Haematologica. 2016 In Process GET IT
Times cited: 0
Clofarabine as a bridge to hematopoietic stem cell transplant. Leukemia & lymphoma. 2016 In Process GET IT
Times cited: 0
Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment. Clinical lymphoma, myeloma & leukemia. 2016 In Process GET IT
Times cited: 0
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. The lancet oncology. 2016 In Process GET IT
Times cited: 1
Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. Leukemia. 2016 In Process GET IT
Times cited: 1
Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia. Future oncology (London, England). 2016 In Process GET IT
Times cited: 1
MSI2 is required for maintaining activated myelodysplastic syndrome stem cells. Nature communications. 2016 In Process GET IT
Times cited: 1
A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 Species. Cell reports. 2015 In Process GET IT
Times cited: 1
Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?. American journal of hematology. 2015 In Process GET IT
Times cited: 1
Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents. Leukemia research. 2015 In Process GET IT
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. The lancet oncology. 2015 In Process GET IT
Times cited: 15
Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome. Leukemia & lymphoma. 2015 In Process GET IT
Times cited: 1
Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells. Cytometry. Part A : the journal of the International Society for Analytical Cytology. 2015 In Process GET IT
Evolving treatments in acute myeloid leukemia. Clinical advances in hematology & oncology : H&O. 2015 Academic Article
Times cited: 0
Prevalence, management, and clinical consequences of QT interval prolongation during treatment with arsenic trioxide. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Academic Article GET IT
Times cited: 7
Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia. Molecular cancer therapeutics. 2014 In Process GET IT
Times cited: 7
International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Academic Article GET IT
Times cited: 21
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Science translational medicine. 2014 In Process GET IT
Times cited: 279
Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation. British journal of haematology. 2014 Academic Article GET IT
Times cited: 11
Standardizing the initial evaluation for myelodysplastic syndromes. Current hematologic malignancy reports. 2013 In Process GET IT
Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia. Leukemia & lymphoma. 2013 In Process GET IT
Times cited: 36
A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute leukemia. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2013 In Process GET IT
Times cited: 3
Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignancies. Leukemia & lymphoma. 2013 Academic Article GET IT
Times cited: 34
A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine. Leukemia & lymphoma. 2013 Academic Article GET IT
Times cited: 27
Pregnancy in a woman with chronic neutrophilic leukemia. Obstetrics and gynecology. 2013 Academic Article GET IT
Times cited: 0
Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium. Leukemia research. 2012 Review GET IT
Times cited: 12
Current treatment of acute myeloid leukemia. Current opinion in oncology. 2012 Review GET IT
Times cited: 47
RBC-transfusion guidelines update. Leukemia research. 2012 Letter GET IT
Times cited: 4
Are low-intensity induction strategies better for older patients with acute myeloid leukemia?. Leukemia research. 2012 Academic Article GET IT
Times cited: 6
Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia. Blood. 2012 Academic Article GET IT
Times cited: 16
Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. Blood. 2011 Academic Article GET IT
Times cited: 59
Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome. Leukemia research. 2011 Academic Article GET IT
Times cited: 7
First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Academic Article GET IT
Times cited: 83
Novel approaches to the treatment of acute myeloid leukemia. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2011 Review GET IT
Times cited: 48
What are RBC-transfusion-dependence and -independence?. Leukemia research. 2011 Letter GET IT
Times cited: 28
Levels of care: defining best supportive care in elderly patients with acute myeloid leukemia. Current hematologic malignancy reports. 2010 Review GET IT
Times cited: 4
Acute myeloid leukemia stem cells: seek and destroy. Expert review of hematology. 2009 Review GET IT
Times cited: 21
Pomalidomide is active in the treatment of anemia associated with myelofibrosis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 137
Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial. Leukemia & lymphoma. 2009 Academic Article GET IT
Times cited: 21
Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 125
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide. Blood. 2009 Academic Article GET IT
Times cited: 46
A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Blood. 2009 Academic Article GET IT
Times cited: 91
Chemotherapy Foundation Symposium XXVI: Innovative cancer therapy for tomorrow - Voreloxin for acute myelogenous leukemia. P and T. 2008 Conference Paper
Times cited: 0
Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia. Cancer. 2008 Academic Article GET IT
Times cited: 37
On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia. Leukemia. 2008 Academic Article GET IT
Times cited: 36
Arsenic and old lace: novel approaches in elderly patients with acute myeloid leukemia. Seminars in hematology. 2008 Review GET IT
Times cited: 5
Systemic antineutrophil cytoplasmic antibody vasculitis in a patient with chronic lymphocytic leukemia: quite a rare diagnosis. Leukemia research. 2007 Academic Article GET IT
Times cited: 8
Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphoma. Leukemia research. 2007 Academic Article GET IT
Times cited: 8
PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia. Leukemia research. 2007 Academic Article GET IT
Times cited: 19
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood. 2007 Academic Article GET IT
Times cited: 283
Treatment of acute myeloid leukemia in older patients. Expert review of anticancer therapy. 2007 Review GET IT
Times cited: 20
Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 66
Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 19
A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia. Leukemia research. 2006 Academic Article GET IT
Times cited: 24
Treatment strategies for acute myeloid leukemia and myelodysplastic syndromes in the elderly population. P and T. 2006 Conference Paper
Times cited: 0
Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Academic Article GET IT
Times cited: 38
A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2006 Academic Article GET IT
Times cited: 7
Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Leukemia. 2006 Academic Article GET IT
Times cited: 68
Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 114
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase. Leukemia research. 2003 Academic Article GET IT
Times cited: 19
The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate. Experimental hematology. 2003 Academic Article GET IT
Times cited: 34
Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia. Leukemia & lymphoma. 2002 Academic Article GET IT
Times cited: 20
Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002 Academic Article GET IT
Times cited: 25
Pentostatin based non-myeloablative conditioning regimen in patients with high-risk hematologic malignancy. Blood. 2000 Academic Article
Times cited: 1
Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood. 2000 Academic Article GET IT
Times cited: 222
Interleukin-5 and the regulation of eosinophil production. Current opinion in hematology. 1999 Review GET IT
Times cited: 46
HIV/AIDS case histories: diagnostic problems. Hodgkin's disease, mixed cellularity type. AIDS patient care and STDs. 1999 Academic Article GET IT
Times cited: 0
Hepatitis C and B-cell lymphoma. AIDS patient care and STDs. 1998 Academic Article GET IT
Times cited: 6
Epidermal growth factor and basic fibroblast growth factor have independent actions on mesencephalic dopamine neurons in culture. Journal of neurochemistry. 1994 Academic Article GET IT
Times cited: 39

more ...

less ...

Research

Sort by

Co-investigator Network

Grants awarded

Arsenic Trioxide in Combination with Cytosine Arabinoside in Patients with Advanced or Transformed Myelofibrosis Principal Investigator 2007 - 2009
Leukemia Clinical Trials Data Manager Support Principal Investigator 2004 - 2005
Leukemia Program Staff Support Principal Investigator 2003 - 2004

Strategies to Eliminate Chemoresistant Leukemia Stem Cells During Remission awarded by Leukemia & Lymphoma Society Key Personnel 2012 - 2016
Pharmacological Modulation of Epigenetic Changes in AML awarded by National Cancer Institute Key Personnel 2013 - 2016
Identification of Novel Therapies to Ablate Chemoresistant Myeloid Leukemia Stem Cells during Remission awarded by National Institutes of Health, Office of the Director Key Personnel 2010 - 2015
Mechanisms Determining Disease Relapse in Older Patients with Acute Myeloid Leukemia awarded by Starr Cancer Consortium Key Personnel 2010 - 2012
Clinical and Translational Science Center (UL1) - Cooperative Agreement Key Personnel 2007 - 2012
Early Therapeutics Development with Phase II Emphasis awarded by National Cancer Institute Key Personnel 2006 - 2011
Pharmacological Modulation of Epigenetic Changes in AML awarded by National Cancer Institute Key Personnel 2015 -
Clinical and Translational Science Center (UL1) - Cooperative Agreement awarded by National Center for Advancing Translational Sciences Key Personnel 2012 -

Novel Strategy to Target Leukemia Stem Cells awarded by Leukemia & Lymphoma Society Principal Investigator Subaward 2008 - 2009

Phase II Study of Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk Adapted Postremission Therapy Principal Investigator Subcontract 2012 - 2015

more ...

less ...

Background

Education and Training

M.D. in Medicine, Mount Sinai School of Medicine 1994
B.A., Yale University 1990

Contact

full name

Dr. Gail J Roboz,

primary email

gar2001@med.cornell.edu

Other

Primary Affiliation

Weill Cornell Medical College, Cornell University

VIVO Weill Cornell Medical College

Gail J Roboz Professor of Medicine

Publications

Selected publications

Research

Grants awarded

Background

Education and Training

Contact

full name

primary email

Other

Primary Affiliation

Phone

Publications

Selected publications

Research

Grants awarded

Background

Education and Training

Contact

full name

primary email

Other

Primary Affiliation